Roundtable: Focus on Multiple Myeloma

A collection of Roundtable discussions focused on important news and updates in multiple myeloma.

Advertisement
Advertisement
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel considers where CAR T-cell therapy should fit in the myeloma treatment paradigm.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel compares clinical trial and real-world data for CAR-Ts.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discusses treatment-related side effects such as CRS, ICANS, and more.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
Drs. Raje and Patel discuss how they decide between CAR-T and bispecifics for their myeloma patients.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discusses which patients may not be suitable for CAR T-cell therapy.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discussed how CAR-T impacts myeloma standard of care.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panelists highlight key data presented at ASCO 2023.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | March 15, 2024
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel considers triplet versus quadruplet therapy for myeloma induction.
Thomas Martin, MDVideo Insights | May 15, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 25, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 3, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
Thomas Martin, MDVideo Insights | May 5, 2023
The panel addresses the potential for frontline CAR-T use.
Thomas Martin, MDVideo Insights | May 3, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
Thomas Martin, MDVideo Insights | May 4, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Thomas Martin, MDVideo Insights | May 5, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
Thomas Martin, MDVideo Insights | May 4, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
Thomas Martin, MDVideo Insights | May 4, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Thomas Martin, MDVideo Insights | May 5, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
Thomas Martin, MDVideo Insights | May 5, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
Advertisement
Advertisement